key: cord-0912494-ikqxls8g
authors: Gaspari, Valeria; Zengarini, Corrado; Greco, Sonia; Vangeli, Valeria; Mastroianni, Antonio
title: Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports
date: 2020-05-22
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106023
sha: c39e3d053d8e0d0889905718c7f08d6911b2d4dd
doc_id: 912494
cord_uid: ikqxls8g

• Innovative drugs are not always available in emergency settings; • Use of ruxolitinib in patients with COVID-19 has given unsatisfactory results; • Janus kinase (JAK) inhibitors may be associated with a major incidence of side effects in COVID-19 patients.

Valeria Gaspari 1 , MD, PhD, Corrado Zengarini 1* , MD, Sonia Greco 2 , MD, Valeria Vangeli 2 , MD, Tocilizumab has been used to control the high levels of cytokines, particularly interleukin-6, produced in certain COVID-19 patients to decrease the immune system response and thus reduce potential lung damage [1] .

We achieved some satisfactory results using tocilizumab, but the drug became temporarily unavailable because of sudden supply issues. We then evaluated the appropriateness of influencing the systemic immune-inflammatory state with compassionate use of ruxolitinib in two patients. This led to unexpected results. A week later, levels of C-reactive protein (CRP), interleukin-6, lactate dehydrogenase (LDH) and haptoglobin increased again, despite clinical stability.

To prevent a relapse, on the sixth week, ruxolitinib 5 mg was administered 2 tablets per day for 2 days, and 4 tablets per day for 3 days, then precociously tapered. Treatment with ruxolitinib was suspended because of the appearance of purpuric lesions on the skin of the dorsal and upper limbs, with concomitant reduction in platelet levels (from 141.000 to 61.000) in 5 days and a deep tissue infection of the left arm. Treatment with steroids and antibiotics was initiated.

Case 2 was a 63-year-old Caucasian woman with a history of hypothyroidism treated with levothyroxine. She reported fever and mild dyspnoea. On the tenth day, she had a positive SARS-CoV-2 nasal swab and was admitted to hospital. Therapy was initiated with enoxaparin Haemodynamic and laboratory values (including interleukin-6) remained acceptable. The patient required prolonged low-volume oxygen therapy and compassionate use of ruxolitinib was needed.

On the twelfth day after admission, the patient was started on ruxolitinib 50 mg 2 times per day for 3 days, and then the dose was doubled. On the day ruxolitinib was doubled the SARS-CoV-2 swab was negative; however, due to the onset of a troublesome herpes labialis, ruxolitinib was then reduced to 50 mg/day and acyclovir therapy was initiated. Four days later, haematocrits showed a progressive reduction of haemoglobin values to 8.7 g/dL and the patient developed an erythrodermic rash on her whole body surface [ Figure 1 ]. Ruxolitinib was promptly stopped and steroid therapy was administered for 5 days.

Ruxolitinib is used for the treatment of intermediate-or high-risk myelofibrosis and polycythaemia vera. This drug inhibits janus kinase (JAK) enzymes, with selectivity for subtypes JAK1 and JAK2, which are often dysregulated in myelopathies [2] .

In addition, ruxolitinib may reduce expression of related genes, and thus the inflammatory response, by altering signal transducers and activators of transcription (STATs) linked to cytokine receptors Severe drug reactions were observed after administering ruxolitinib at two different stages of COVID-19 in the two cases reported here. In the first case, the patient had high levels of inflammatory markers and poor respiratory function, which are indications for the use of tocilizumab [1] , and was treated with ruxolitinib 7 weeks after first symptoms (the patient had received tocilizumab up until the week before). In the second case, ruxolitinib was given 13 days after onset of symptoms to a moderately stable patient to prevent worsening of symptoms. The timing of initiation of treatment with ruxolitinib and the severity of illness differed in these two patients; however, both patients were required to stop ruxolitinib treatment earlier than expected.

This was because the first patient developed a soft-tissue infection and both patients developed cutaneous reactions with purpuras and a rapid drop in haematocrit values. Such side effects were probably worsened by the association with ritonavir, an inhibitor of CYP3A4, which may have increased ruxolitinib serum concentration [5] .

In our opinion, the role of ruxolitinib as an immunomodulating drug in SARS-CoV-2 infection needs to be better defined in terms of safety and management of its potentially severe side effects, particularly in multidrug regimens with antiretroviral therapies.

Funding: None

The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality

Managing side effects of JAK inhibitors for myelofibrosis in clinical practice

COVID-19: combining antiviral and anti-inflammatory treatments

Exploring the relevance of senotherapeutics for the current SARS-CoV-2 emergency and similar future global health threats

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 Phosphate) in healthy volunteers

C: diffuse, erythematous, non-bleaching, eruptive reaction, probably of vasculitic origin, on the second day of ruxolitinib administration

Ethical Approval: Not required